

Association of Candesartan vs Losartan With All-Cause Mortality in Patients With Heart Failure

Maria Eklind-Cervenka, MD

Lina Benson, MSc

Ulf Dahlström, MD, PhD

Magnus Edner, MD, PhD

Mårten Rosenqvist, MD, PhD

Lars H. Lund, MD, PhD

ANGIOTENSIN II RECEPTOR blockers (ARBs) reduce cardiovascular mortality and heart failure (HF) hospitalization in patients with HF with reduced left ventricular ejection fraction (LVEF).¹ In patients not taking an angiotensin-converting enzyme (ACE) inhibitor and when added to an ACE inhibitor, candesartan and valsartan reduced the combined end point mortality and HF hospitalizations and morbidity.²⁻⁴ When compared with captopril, losartan was neutral with regard to all-cause mortality and HF hospitalization.⁵ A losartan dose of 150 mg/d compared with a dose of 50 mg/d reduced combined cardiovascular mortality and HF hospitalization.⁶ In contrast, ARBs do not appear to be effective in HF with preserved LVEF,⁷ although candesartan reduced HF hospitalization.⁸

Despite these variable effects, different ARBs have not been tested head to head. Major cardiology societies recommend ARBs for the treatment of HF with reduced LVEF but do not specify agents.^{9,10} However, there are reasons to believe different agents may have different efficacy. Candesartan com-

Context Angiotensin II receptor blockers (ARBs) reduce combined mortality and hospitalization in patients with heart failure (HF) with reduced left ventricular ejection fraction. Different agents have different affinity for the AT₁ receptor and may have different clinical effects, but have not been tested against each other in HF.

Objective To assess the association of candesartan vs losartan with all-cause mortality in patients with HF.

Design, Setting, and Patients An HF registry (the Swedish Heart Failure Registry) of 30 254 unique patients registered from 62 hospitals and 60 outpatient clinics between 2000 and 2009. A total of 5 139 patients (mean [SD] age, 74 [11] years; 39% women) were treated with candesartan (n=2639) or losartan (n=2500). Survival as of December 14, 2009, by ARB agent was analyzed by Kaplan-Meier method and predictors of survival determined by univariate and multivariate proportional hazard regression models, with and without adjustment for propensity scores and interactions. Stratified analyses and quantification of residual confounding were also performed.

Main Outcome Measures All-cause mortality at 1 and 5 years.

Results One-year survival was 90% (95% confidence interval [CI], 89%-91%) for patients receiving candesartan and 83% (95% CI, 81%-84%) for patients receiving losartan, and 5-year survival was 61% (95% CI, 54%-68%) and 44% (95% CI, 41%-48%), respectively (log-rank *P* < .001). In multivariate analysis with adjustment for propensity scores, the hazard ratio for mortality for losartan compared with candesartan was 1.43 (95% CI, 1.23-1.65; *P* < .001). The results persisted in stratified analyses.

Conclusion In this registry of patients with HF, the use of candesartan compared with losartan was associated with a lower mortality risk.

JAMA. 2011;305(2):175-182

www.jama.com

pared with losartan has higher binding affinity for the AT₁ receptor,^{11,12} is more effective at lowering blood pressure,¹³ and is associated with less de novo HF when used in hypertension.¹⁴ In elderly patients with HF, losartan was associated with higher mortality than other ARBs.¹⁵

Randomized controlled trials (RCTs) minimize bias and confounding but have not been performed to address this issue. Therefore, our goal was to determine whether candesartan is asso-

Author Affiliations: Department of Cardiology, South Hospital, Stockholm (Drs Eklind-Cervenka and Rosenqvist); Karolinska Institutet, Department of Clinical Science and Education, SöS, Stockholm (Drs Eklind-Cervenka and Rosenqvist and Ms Benson); Department of Cardiology, Linköping University Hospital, and Department of Medical and Health Sciences, Linköping University, Linköping (Dr Dahlström); Division of Cardiovascular Medicine, Danderyd Hospital, and Karolinska Institutet, Department of Clinical Sciences, Danderyd, Stockholm (Dr Edner); and Department of Cardiology, Karolinska University Hospital, and Karolinska Institutet, Department of Medicine, Stockholm (Dr Lund), Sweden.

Corresponding Author: Lars H. Lund, MD, PhD, Department of Cardiology, Karolinska University Hospital, N305, 171 76 Stockholm, Sweden (lars.lund@alumni.duke.edu).

ciated with less all-cause mortality than losartan in a large cohort of unselected patients with HF.

METHODS

Study Protocol

The Swedish Heart Failure Registry (RiksSvikt) has been previously described.¹⁶ It was created as a pilot in 2000 and introduced throughout Sweden in 2003. Inclusion criteria are clinician-judged HF. Approximately 70 variables are recorded at discharge from hospital or after clinic visit on a case report form and entered into a database managed by the Uppsala Clinical Research Center, Uppsala, Sweden. The database is run against the Swedish death registry monthly. The protocol, registration form, and annual report are available at <http://www.ucr.uu.se/rikssvikt>. Establishment of the registry and registration and analysis of the data was approved by a multisite ethics committee. Individual patient consent was not required or obtained.

As of December 14, 2009, there were 44 548 registrations from 30 254 unique patients from 62 hospitals and 60 outpatient clinics. Of 30 254 unique patients, 5823 received an ARB (2639 received candesartan, 2500 received losartan, 357 received valsartan, and 327 received other ARBs) at the time of the first registration. Valsartan and other ARBs were excluded due to small numbers, resulting in 5139 individuals receiving candesartan (n=2639) or losartan (n=2500) for this study.

Statistical Analysis

To avoid bias due to missing baseline characteristics, multiple imputation (n=10) was performed for variables with missing data using predictive mean matching. All subsequent analyses, except for descriptive statistics, were performed on the imputed data. To adjust for selection bias, propensity scores for each patient were estimated with logistic regression. Quintiles of the estimated propensity scores were used to divide the patients into 5 strata.¹⁷ All patient and medical history and treatment variables (excluding outcome

variables and target dose ARB with losartan dose set at 150 mg/d) were used when creating the multiple imputation data sets as well as in the estimation of the propensity scores. To evaluate the propensity scores, logistic regressions with ARB agent as outcome were performed for each of the variables with and without adjustment for propensity score strata.

Survival was charted by Kaplan-Meier method and compared with the log-rank test for all patients and separately for an LVEF of less than 40% and 40% or more. Several univariate and multivariate proportional hazard regression models with and without adjustment for interactions and propensity scores, as a covariate and strata variable, were performed, with ARB agent adjusted for single or combinations of clinically relevant variables.

Interactions between ARB agent and clinically relevant variables were estimated by a Cox proportional hazards regression model and are shown in a Forest plot. Interactions with ARB were tested for all variables in the model. The scaled Schoenfeld residuals from the proportional hazards regression model were investigated to assess the proportional hazards assumption, whereas the Martingale residuals were visually inspected to detect possible nonlinearity for the continuous variables.

Stratifications were performed by 5 clinically important variables that may affect choice of agent, prognosis, or both (year of inclusion [2001-2005 vs 2006-2009], duration of HF [<6 vs ≥ 6 months], age [≤ 70 vs >70 years], New York Heart Association [classes I-II {mild} vs III-IV {moderate to severe}], and LVEF [$<40\%$ vs $\geq 40\%$]). Losartan was available before candesartan and the cutoff at 2005-2006 was chosen because the European and US guidelines reflecting the CHARM studies^{2,3,8,18} were published in 2005.^{19,20}

A sensitivity analysis was performed to evaluate the effect of a possible unknown or unmeasured confounder.²¹ Hazard ratios (HRs) for

losartan vs candesartan adjusted for an unknown binary or continuous (normally distributed) confounder was derived assuming different hazards and distributions of the unmeasured confounder in the 2 treatments.

One clinically relevant and prespecified subgroup analysis was performed by LVEF, divided by less than 40% (n=2608) and 40% or more (n=1884) (647 patients had missing LVEF data). We also performed a prespecified analysis with target dose of 150 mg/d rather than 50 mg/d for losartan, in accordance with the HEAAL study.⁶

To test the null hypothesis that there is no difference in survival between candesartan and losartan at 1 year, 2270 patients would be needed (1135 in each group). This assumed an annual mortality rate of 8.1% (candesartan group in the CHARM-Overall trial¹⁸) and 11.7% (losartan group in the ELITE II trial³), respectively; a power of 80%; and that the 2-sided level of significance was set at .05. Statistics were performed in R version 2.9.2 (R Foundation for Statistical Computing, Vienna, Austria).

RESULTS

Baseline characteristics and *P* values of patients and medical history and treatment for imputed data showing differences before and after adjustment for propensity scores strata are shown in TABLE 1 and TABLE 2. A total of 5139 patients were included (mean [SD] age, 74 [11] years; 39% women) in the analyses. Patients receiving candesartan were overall healthier but had lower LVEF and were less likely to reach target doses (defined as 32 mg/d and 50 mg/d for candesartan and losartan, respectively). If the target dose was set at 150 mg/d for losartan,⁶ there were still more patients in the candesartan group receiving 25% or less of the target dose. The unadjusted logistic regressions revealed a number of differences in baseline characteristics between patients receiving losartan and candesartan, but after adjustment for propensity scores, there were no longer any statistically significant differences, except for dose

of ARB, with target dose set at 150 mg/d. This target dose was analyzed as a prespecified sensitivity analysis but a target dose of 50 mg/d was chosen for inclusion in multiple imputation and derivation of propensity scores. One variable, ACE inhibitor, had a *P* value of less than .10 (*P* = .07).

FIGURE 1 shows the overall survival between the 2 groups. One-year survival was 90% (95% confidence interval [CI], 89%-91%) for patients receiving candesartan and 83% (95% CI, 81%-84%) for patients receiving losartan, and 5-year survival was 61% (95% CI, 54%-68%) for patients receiving candesartan and 44% (95% CI, 41%-48%) for patients receiving losartan (log-rank *P* < .001). TABLE 3 shows HRs for all-cause mortality in patients receiving losartan vs candesartan. The univariate HR was 1.77 (95% CI, 1.58-1.99; *P* < .001) and the multivariate HR including stratification for propensity scores was 1.43 (95% CI, 1.23-1.65; *P* < .001) (HR = 0.70 for candesartan vs losartan). Only β -blockers interacted with an ARB agent (*P* = .04). TABLE 4 shows HRs for all-cause mortality for patients receiving losartan vs candesartan after adjustment for this interaction, together with interactions with 4 variables with *P* < .10 (cardiac resynchronization therapy, duration of HF, creatinine, and lung disease). Losartan remained associated with increased mortality compared with candesartan for all categories except cardiac resynchronization therapy and lung disease.

Violations to the proportional hazards assumption were detected for location and this variable was therefore included as a strata variable in all proportional hazards regression models. Stratification did not change the results. Multivariate HRs with propensity score strata were 1.41 (95% CI, 1.22-1.64; *P* < .001) for year of inclusion; 1.43 (95% CI, 1.23-1.67; *P* < .001) for HF duration; 1.48 (95% CI, 1.28-1.72; *P* < .001) for age; 1.43 (95% CI, 1.24-1.67; *P* < .001) for NYHA class; and 1.44 (95% CI, 1.24-1.67; *P* < .001) for LVEF.

Quantification of the effects of a hypothetical confounder were calculated (eTable, available at <http://www>

.jama.com). Given an HR of 2 for all-cause mortality for the binary confounder and an approximate differ-

Table 1. Baseline Patient Characteristics and *P* Values for Imputed Data Before and After Adjustment for Propensity Scores Strata^a

Characteristics	Candesartan (n = 2639)	Losartan (n = 2500)	P Value	
			Imputed	Imputed Stratified for Propensity Score
Follow-up time, median (range), d	563.0 (0-2565)	640.5 (0-2916)		
No. of dead	441	888		
Included in the Swedish Heart Failure Registry				
2001-2005	214 (8.1)	701 (28.0)	<.001	.13
2006-2009	2425 (91.9)	1799 (72.0)		
Age, mean (SD), y	72.0 (11.5)	75.3 (10.2)	<.001	.54
Sex				
Male	1633 (61.9)	1483 (59.3)	.06	.86
Female	1006 (38.1)	1017 (40.7)		
Civil status				
Married	1621 (64.6)	1378 (60.1)	<.001	.92
Single	890 (35.4)	916 (39.9)		
Clinic				
Medicine	1116 (44.6)	1123 (47.7)	.001	.91
Cardiology	1371 (54.8)	1198 (50.9)		
Geriatric	14 (0.6)	32 (1.4)		
Location				
Inpatient	1202 (45.5)	1519 (61.8)	<.001	.67
Outpatient	1437 (54.5)	981 (39.2)		
Duration of heart failure, mo				
<6	1061 (40.2)	736 (29.4)	<.001	.57
≥6	1578 (59.8)	1764 (70.6)		
NYHA class ^b				
I	234 (11.0)	164 (9.0)	<.001	.98
II	1068 (50.0)	734 (40.3)		
III	770 (36.0)	840 (46.2)		
IV	65 (3.0)	82 (4.5)		
LVEF, %				
<30	692 (29.0)	628 (29.8)	.02	>.99
30-39	701 (29.4)	587 (27.9)		
40-49	511 (21.4)	404 (19.2)		
≥50	481 (20.2)	488 (23.2)		
QRS duration, mean (SD), ms	111.9 (28.9)	114.0 (28.2)	<.001	.93
Potassium, mean (SD), mEq/L	4.5 (1.2)	4.4 (1.1)	<.001	.76
Heart rate, mean (SD), beats/min	71.9 (14.8)	72.7 (14.7)	.09	>.99
Creatinine, mean (SD), mg/dL	1.25 (0.64)	1.37 (0.70)	<.001	.61
MAP, mean (SD), mm Hg	92.6 (13.9)	91.5 (13.4)	.003	.79
Hemoglobin, mean (SD), g/dL	13.3 (1.7)	13.1 (1.7)	<.001	.84
Smokers				
Current	207 (10.0)	172 (9.4)	.41	>.99
Former	934 (45.0)	868 (47.4)		
Never	935 (45.0)	791 (43.2)		

Abbreviations: LVEF, left ventricular ejection fraction; MAP, mean arterial pressure; NYHA, New York Heart Association.

SI conversions: To convert creatinine to $\mu\text{mol/L}$, multiply by 88.4; hemoglobin to g/L, multiply by 10.0.

^aData are presented as No. (%) unless otherwise specified. Percentages may not total 100 due to rounding.

^bNYHA class I indicates no symptoms; NYHA class II, symptoms with moderate exertion; NYHA class III, symptoms with mild exertion; and NYHA class IV, symptoms at rest.

ence of 30% between the 2 ARBs in the probability of having the confounder, the HR for losartan vs candesartan would no longer be statistically significant. Alternatively, the corresponding numbers would have to be an HR of 3 and a difference in probability of 20% (eTable). For a normally distributed continuous confounder, if the difference in mean units between the 2 ARBs were at least 0.3 and the HR for the confounder were larger than 1.005 per unit,

the HR for losartan vs candesartan would no longer be statistically significant (eTable).

In prespecified subgroup analysis according to LVEF, patients with an LVEF of 40% or more were older, more commonly women, and had more atrial fibrillation, but were otherwise healthier than patients with an LVEF of less than 40%. For patients with an LVEF of less than 40%, 1-year survival for candesartan and losartan was 91% (95% CI, 89%-92%) and 82% (95% CI, 80%-85%), respectively; and 5-year survival was 68% (95% CI, 60%-76%) and 44% (95% CI, 40%-49%), respectively ($P < .001$). For patients with an LVEF of 40% or more, the corresponding data for candesartan and losartan were 91% (95% CI, 89%-93%) and 86% (95% CI, 83%-88%) for 1-year survival and 54% (95% CI, 40%-72%) and 50% (95% CI, 44%-56%) for 5-year survival, respectively ($P < .001$).

The HRs for losartan vs candesartan were similar for an LVEF of less than 40% and an LVEF of 40% or more, and similar to the whole population (all were statistically significant in favor of candesartan). For an LVEF of less than 40%, the univariate HR was 2.08 (95% CI, 1.76-2.46; $P < .001$) and the multivariate HR including propensity score strata was 1.41 (95% CI, 1.14-1.76; $P = .002$). For an LVEF of 40% or more, the univariate HR was 1.42 (95% CI, 1.17-1.73; $P < .001$) and the multivariate HR including propensity score strata was 1.37 (95% CI, 1.06-1.79; $P = .02$). When the target dose of losartan was set at 150 mg/d, the HR adjusted only for dose was 1.91 ($P < .001$) and the HR from the multivariate model stratified for propensity score strata was 1.36 ($P = .02$). The propensity scores and the multiple imputations used in the LVEF subgroup and losartan dose of 150 mg/d analyses were the same as those derived for the full population and target dose of losartan of 50 mg/d.

No additional subgroup analyses were performed. However, interactions between ARB agent and clinical parameters were estimated and are shown in FIGURE 2.

Table 2. Baseline Characteristics of Medical History and Treatment and *P* Values for Imputed Data Before and After Adjustment for Propensity Scores Strata

Characteristics	No. (%) of Patients		<i>P</i> Value	
	Candesartan (n = 2639)	Losartan (n = 2500)	Imputed	Imputed Stratified for Propensity Score
Medical History				
Hypertension	1411 (55.0)	1296 (53.7)	.40	.88
Ischemic heart disease	1286 (50.7)	1461 (60.6)	<.001	.70
Dilated cardiomyopathy	366 (14.4)	297 (12.5)	.06	.93
Hypertrophic cardiomyopathy	49 (1.9)	63 (2.7)	.09	.88
Valve disease	468 (18.4)	501 (21.4)	.01	.78
Atrial fibrillation	1149 (43.8)	1222 (49.4)	<.001	.91
Diabetes mellitus	764 (29.2)	844 (34.0)	<.001	.94
Lung disease	413 (16.2)	515 (21.3)	<.001	.87
History of PCI and/or CABG surgery	773 (29.7)	803 (33.0)	.02	.93
Pacemaker	298 (11.4)	382 (15.5)	<.001	>.99
Cardiac resynchronization therapy	78 (3.0)	105 (4.3)	.01	.95
Implantable cardioverter defibrillator	87 (3.3)	96 (3.9)	.24	.97
Heart transplantation	7 (0.3)	12 (0.5)	.22	.97
Medical Treatment				
ACE inhibitor	420 (16.0)	76 (3.1)	<.001	.07
β-Blocker	2295 (87.1)	2049 (82.3)	<.001	.73
Aldosterone antagonist	802 (30.6)	904 (36.4)	<.001	.84
Diuretic	2065 (78.4)	2190 (87.8)	<.001	.74
Digoxin	440 (16.8)	500 (20.1)	.002	.88
Insulin	416 (15.9)	484 (19.5)	<.001	.93
Oral antidiabetic	362 (13.8)	380 (15.3)	.11	>.99
Aspirin	1281 (48.7)	1260 (50.5)	.19	.81
Oral anticoagulants	1056 (40.2)	997 (40.1)	.93	.89
Statin	1335 (50.8)	1245 (50.0)	.56	.95
Nitrates	459 (17.5)	632 (25.4)	<.001	.61
Amiodarone	81 (3.3)	84 (3.6)	.61	.87
Sotalol	14 (0.5)	29 (1.2)	.02	.87
Inotropic agent	35 (1.4)	44 (1.9)	.21	.92
Target dose of ARB				
Losartan, 50 mg/d				
≤25%	970 (36.8)	204 (8.2)	<.001	.24
26%-50%	714 (27.1)	330 (13.2)		
51%-75%	77 (2.9)	15 (0.6)		
≥76%	878 (33.3)	1951 (78.0)		
Losartan, 150 mg/d				
≤25%	970 (36.7)	549 (22.0)	<.001	<.001
26%-50%	714 (27.1)	1501 (60.0)		
51%-75%	77 (2.9)	445 (17.8)		
≥76%	878 (33.3)	5 (0.2)		

Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor blocker; CABG, coronary artery bypass graft; PCI, percutaneous coronary intervention.

COMMENT

Our findings show that in an unselected HF population, candesartan was associated with lower all-cause mortality compared with losartan. The difference was significant even after adjustment for propensity scores and numerous clinical variables, including dose, potential interactions, and after stratification and quantification of potential residual confounding of a reasonable magnitude. The variables adjusted for included those that might affect choice of agent (selection bias) and outcome (confounders). However, we cannot eliminate the possibility that residual confounding explains some of the association. In prespecified subgroups, our findings persisted with both an LVEF of less than 40% and an LVEF of 40% or more.

There are mechanistic reasons to believe candesartan may be more effective than losartan. Angiotensin II receptor blockers competitively block the AT₁ receptor. Candesartan has 4 binding sites on the AT₁ receptor and losartan has 2 binding sites.²² In vitro studies have shown that losartan binds loosely and has a dissociation half-life of seconds to minutes, yielding “surmountable” antagonism. Candesartan binds tightly and has a dissociation half-life of 120 minutes, yielding “insurmountable” antagonism. Losartan has an active metabolite EXP3174, but even this has looser binding to the AT₁ receptor.^{11,23-25} A point mutation at Lys¹⁹⁹ decreases the affinity 45-fold for candesartan but only 5-fold for losartan.²⁶ Rat studies have shown candesartan to be 10 to 30 times more potent than losartan, and concentrations required for displacement of 50% radioligand were 0.9 nmol/L for candesartan and 8.9 nmol/L for losartan.¹²

Clinical studies in hypertension also suggest that candesartan may be more effective than losartan. Both candesartan (16 mg/d) and losartan (100 mg/d) improved endothelial function, measured by flow-mediated vasodilation, but only candesartan lowered plasma levels of plasminogen activator inhibitor 1 and monocyte chemoattractant

protein 1.²⁷ Candesartan inhibited the angiotensin II-induced increase in renal filtration fraction and the aldosterone secretion significantly more than losartan.²⁸ Candesartan (16 mg/d) compared with losartan (100 mg/d) was more effective at lowering blood pressure, and after a forced missed dose, patients receiving losartan but not candesartan returned to pretreatment blood pressure,²⁹ consistent with the affinity observations above. A meta-analysis suggests that candesartan is more effective at lowering blood pressure.¹³ In a registry study of hypertension, candesartan compared with losartan was associated with less de novo HF¹⁴ and, in a registry study of elderly patients with HF, losartan was associated with worse survival than irbesartan, valsartan, and candesartan.¹⁵

In HF, ARBs have not been compared head to head, but studies of candesartan are larger and more conclusively positive than studies of losartan. The CHARM program is the largest and most positive and conclusive set of studies.^{2,3,8,18} A meta-analysis of 38 080 patients from 24 trials revealed that most studies comparing ARB vs placebo were with candesartan and yielded a reduction in both mortality (odds ratio [OR], 0.83; 95% CI, 0.69-1.00) and HF hospitalization (OR, 0.64; 95% CI, 0.53-0.78); most studies comparing ARB vs ACE inhibitors were with losartan and yielded neutral effects (OR, 1.06; 95% CI, 0.90-1.26 for mortality and OR, 0.95; 95% CI, 0.80-1.13 for HF hospitalization); and most studies of ARB on top of ACE inhibitors were with candesartan and were overall neutral with respect to mortality (OR, 0.97; 95% CI, 0.87-1.08) but beneficial with respect to HF hospitalization (OR, 0.77; 95% CI, 0.69-0.87).¹

Registry studies have advantages compared with RCTs. Inherent to RCTs are strict inclusion/exclusion criteria that limits applicability to many patient groups (eg, elderly patients). Patients are carefully monitored, which may dilute any differences between therapies had they played out under normal clinical follow-up. Strict inclu-

sion criteria and careful monitoring also yield good prognosis. Indeed, RCTs of ARBs have attempted to augment risk by requiring hospitalization before inclusion but have still mainly demonstrated reductions in disease-specific morbidity such as HF hospitalization rather than all-cause mortality.³⁰ In contrast, our registry study provides information useful for every day clinical care of a broad unselected HF population,

Figure 1. Kaplan-Meier Estimates of Survival of Patients Receiving Candesartan and Losartan




Table 3. Proportional Hazard Regression Models for All-Cause Mortality for Losartan vs Candesartan^a

Losartan vs Candesartan	Hazard Ratio (95% CI)
Univariate model	1.77 (1.58-1.99)
Multivariate model	
Adjusted for age and sex	1.56 (1.39-1.75)
Adjusted for duration of heart failure	1.71 (1.52-1.92)
Adjusted for hypertension	1.77 (1.58-1.99)
Adjusted dose of 50 mg/d ^b	2.53 (2.22-2.88)
Adjusted dose of 150 mg/d ^c	1.91 (1.67-2.18)
Adjusted for ACE inhibitor, β-blocker, and aldosterone antagonist	1.71 (1.52-1.93)
Multivariate final model	
Final	1.43 (1.23-1.65)
With propensity scores covariate	1.41 (1.22-1.64)
With propensity scores strata	1.43 (1.23-1.65)

Abbreviations: ACE, angiotensin-converting enzyme; CI, confidence interval.

^a $P < .001$ for all univariate and multivariate models.

^bTarget dose of 50 mg/d for losartan and 32 mg/d for candesartan.

^cTarget dose of 150 mg/d for losartan and 32 mg/d for candesartan.

and our findings of reduced mortality with candesartan interacted statistically only with β -blocker therapy but no other parameters, making them broadly applicable. The reasons for this interaction are not readily apparent.


Table 4. Multivariate Final Analysis With Propensity Score Strata and Interaction for Losartan vs Candesartan

Multivariate Final Analysis	Hazard Ratio (95% CI)	P Value	
		Main Effect	Interaction
β -Blocker			
No	1.90 (1.39-2.60)	<.001	.04
Yes	1.35 (1.15-1.57)	<.001	.04
Cardiac resynchronization therapy			
No	1.45 (1.25-1.68)	<.001	.09
Yes	0.82 (0.42-1.58)	.55	.09
Duration of heart failure, mo			
<6	1.72 (1.35-2.20)	<.001	.05
\geq 6	1.33 (1.12-1.56)	<.001	.05
Creatinine ^a	1.51 (1.18-1.93)	<.001	.07
Lung disease			
No	1.52 (1.29-1.79)	<.001	.06
Yes	1.17 (0.90-1.51)	.24	.06

Abbreviation: CI, confidence interval.

^aFor creatinine=100 μ mol/L (1.13 mg/dL).

Figure 2. Hazard Ratios for All-Cause Mortality for Losartan vs Candesartan From the Multivariate Model Stratified for Propensity Scores and Interaction With Selected Subgroups



ACE indicates angiotensin-converting enzyme; CI, confidence interval; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association. Continuous and categorical variables with more than 2 levels were dichotomized at clinically relevant cutoff for presentation purposes. For variables with missing data, this number is the mean of the 10 imputations.

The magnitude of the difference in association with mortality was large. The HR for all-cause mortality of losartan compared with candesartan was 1.43 (candesartan vs losartan, 0.70) overall and similar in the LVEF of less than 40% and the LVEF of 40% or more comparisons. In comparison, in the CHARM-Overall study,¹⁸ the adjusted HR for overall mortality was 0.90 ($P=.03$). The adjusted HRs for cardiovascular death and HF hospitalization was 0.70 ($P<.001$) in the CHARM-Alternative study,² 0.85 ($P=.01$) in the CHARM-Added study,³ and 0.86 ($P=.051$) in the CHARM-Preserved study.⁸ The magnitude of our findings may be due to chance, but RCTs may understate “real world” differences, and it is conceivable that candesartan is better than losartan by a magnitude similar to placebo.

The survival in the overall population of our study was quite high. This may be explained by 54.5% of patients being registered as outpatients. Inpatient registration was indeed an independent predictor of mortality. However, inpatient vs outpatient registration did not affect the differences between losartan vs candesartan (location was included in all our models and there was no interaction between ARB agent and location).

Our study has limitations. First, the diagnosis of HF in the Swedish Heart Failure Registry is clinical and does not require objective evidence of HF. A majority of patients had echocardiography data (87%) but only 31% had (N-terminal pro) brain natriuretic peptide, and in patients with preserved LVEF, there were no formal diagnostic criteria. Indeed, a larger proportion of patients with preserved LVEF had concomitant lung disease and some of these may not have had HF. Nonetheless, ARBs are effective mainly in HF with reduced LVEF and, in our study, candesartan was associated with lower mortality than losartan in this subgroup. In a registry study, treatment may change over time and

adherence is not monitored, and our study reflects only agent, dose, and coexisting HF therapy at the time of inclusion. However, this is true in intention-to-treat randomized studies as well.

In addition, our study is limited by its nonrandomized character and there are potential biases and confounders that may be responsible for our findings. First, choice of ARB agent may be subject to selection bias and we cannot determine whether hypertension or HF or diabetes was the primary indication. The Swedish Heart Failure Registry contains clinical variables that may affect choice of agent, such as hypertension, diabetes, and duration of HF. These were accounted for in the derivation of a propensity score for each patient, adjusted for in multivariate regression and examined in tests for interaction with ARB agent (duration of HF was also stratified). Because losartan has been available longer than candesartan, earlier inclusion in the Swedish Heart Failure Registry may entail a higher likelihood of receiving losartan. Indeed, year of inclusion in the Swedish Heart Failure Registry was skewed toward later years for candesartan. However, year of inclusion was corrected for by the propensity score, did not interact with ARB agent, and was stratified for, and candesartan remained associated with lower mortality than losartan.

Second, the efficacy of different ARB agents is subject to confounding. The Swedish Heart Failure Registry contains numerous variables that may affect outcomes independent of ARB agent, such as age, LVEF, NYHA class, renal function, dose of ARB, and treatment with other HF drugs, and patients treated with losartan were less healthy (except for better LVEF). However, these were included in propensity scores and multivariate analysis and examined for interactions with ARB agent. Also, important variables were examined in stratifications, without

changing the results. Earlier inclusion may also entail less utilization of evidence-based therapies. However, concomitant HF therapies were included in the propensity score and multivariate analysis. In addition, the importance of up-titration of doses is well known. Indeed, the HEAAL study⁶ showed that losartan dose of 150 mg/d compared with 50 mg/d was associated with less combined cardiovascular mortality and HF hospitalization. However, even after adjustment for a target dose of 150 mg/d, losartan remained associated with higher mortality than candesartan did in our study.

Nonetheless, we cannot rule out that the benefits with candesartan are due to potential unknown confounders. The quantification of residual confounding suggests that to invalidate the results, a potential confounder or combination of confounders would have to have both a strong association with all-cause mortality and also be considerably likely to affect the choice of losartan vs candesartan. We are unaware of any previously described variables and find it unlikely (but cannot rule out) that there exists unknown variables, which are not adjusted for in our analysis, have a relatively strong association with all-cause mortality, and would be likely to affect the choice of losartan vs candesartan.

In conclusion, our findings suggest that candesartan is associated with less all-cause mortality than losartan. However, clinical decision making should await supportive evidence of this observed association. Ideally, different ARB agents should be tested against each other in RCTs. It would also be important and perhaps more feasible to confirm our findings in other large HF registries.

Author Contributions: Dr Lund and Ms Benson had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Study concept and design: Eklind-Cervenka, Rosenqvist, Lund.

Acquisition of data: Eklind-Cervenka, Dahlström, Edner, Lund.

Analysis and interpretation of data: Eklind-Cervenka, Benson, Dahlström, Edner, Rosenqvist, Lund.

Drafting of the manuscript: Eklind-Cervenka, Edner, Lund.

Critical revision of the manuscript for important intellectual content: Benson, Dahlström, Edner, Rosenqvist, Lund.

Statistical analysis: Eklind-Cervenka, Benson, Edner, Lund.

Obtained funding: Lund.

Administrative, technical, or material support: Dahlström, Edner, Lund.

Study supervision: Edner, Rosenqvist, Lund.

Conflict of Interest Disclosures: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Eklind-Cervenka reported receiving speaker's fees from Astra-Zeneca. Dr Dahlström reported receiving speaker's fees from Astra-Zeneca and research grants from Linköping University, Research Foundation SouthEastern Sweden, and Swedish Heart-Lung Foundation. Dr Edner reported receiving speaker's fees from Merck Sharp and Dohme, and research grants from Karolinska Institutet, Stockholm County Council, Medtronic, St Jude, Boston Scientific, and Merck Sharp and Dohme. Dr Rosenqvist reported receiving consulting fees from Merck Sharp and Dohme, speaker's fees from Astra-Zeneca and Merck Sharp and Dohme, and research grants from Karolinska Institutet, Stockholm County Council, Swedish Heart-Lung Foundation, Vinnova, Swedish Order of Free Mason, Sanofi-Aventis, and Boehringer Ingelheim. Dr Lund reported receiving consulting fees and speaker's fees from Astra-Zeneca, and research grants from Karolinska Institutet, Stockholm County Council, Swedish Heart-Lung Foundation, Astra-Zeneca, and Orion Pharma. Ms Benson reported no financial disclosures.

Funding/Support: This study received no specific funding. However, establishment of the Swedish Heart Failure Registry was supported by the Swedish National Board of Health and Welfare, the Swedish Association of Local Authorities and Regions, the Swedish Society of Cardiology, AstraZeneca, Roche, Merck, Orion Pharma, and ResMed.

Role of the Sponsors: The sponsors had no role in the design and conduct of the study, in the collection, management, analysis, or interpretation of the data, or in the preparation, review, or approval of the manuscript.

Online-Only Material: An eTable is available at <http://www.jama.com>.

REFERENCES

1. Lee VC, Rhew DC, Dylan M, et al. Meta-analysis: angiotensin-receptor blockers in chronic heart failure and high-risk acute myocardial infarction. *Ann Intern Med*. 2004;141(9):693-704.
2. Granger CB, McMurray JJ, Yusuf S, et al; CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. *Lancet*. 2003;362(9386):772-776.
3. McMurray JJ, Ostergren J, Swedberg K, et al; CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. *Lancet*. 2003;362(9386):767-771.
4. Cohn JN, Tognoni G; Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. *N Engl J Med*. 2001;345(23):1667-1675.
5. Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial—the Losartan Heart Failure Survival Study ELITE II. *Lancet*. 2000;355(9215):1582-1587.

6. Konstam MA, Neaton JD, Dickstein K, et al; HEAAL Investigators. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. *Lancet*. 2009;374(9704):1840-1848.
7. Massie BM, Carson PE, McMurray JJ, et al; I-PRESERVE Investigators. Irbesartan in patients with heart failure and preserved ejection fraction. *N Engl J Med*. 2008;359(23):2456-2467.
8. Yusuf S, Pfeffer MA, Swedberg K, et al; CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved trial. *Lancet*. 2003;362(9386):777-781.
9. Dickstein K, Cohen-Solal A, Filippatos G, et al; ESC Committee for Practice Guidelines (CPG). ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. *Eur J Heart Fail*. 2008;10(10):933-989.
10. Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *Circulation*. 2009;119(14):e391-e479.
11. Vanderheyden PM, Fierens FL, De Backer JP, Fraeyman N, Vauquelin G. Distinction between surmountable and insurmountable selective AT1 receptor antagonists by use of CHO-K1 cells expressing human angiotensin II AT1 receptors. *Br J Pharmacol*. 1999;126(4):1057-1065.
12. Fabiani ME, Dinh DT, Nassis L, Casley DJ, Johnston CI. In vivo inhibition of angiotensin receptors in the rat kidney by candesartan cilexetil: a comparison with losartan. *Am J Hypertens*. 2000;13(9):1005-1013.
13. Meredith PA, Murray LS, McInnes GT. Comparison of the efficacy of candesartan and losartan: a meta-analysis of trials in the treatment of hypertension. *J Hum Hypertens*. 2010;24(8):525-531.
14. Kjeldsen SE, Ståhlhammar J, Hasvold P, Bodegard J, Olsson U, Russell D. Effects of losartan vs candesartan in reducing cardiovascular events in the primary treatment of hypertension. *J Hum Hypertens*. 2010;24(4):263-273.
15. Hudson M, Humphries K, Tu JV, Behloul H, Sheppard R, Pilote L. Angiotensin II receptor blockers for the treatment of heart failure: a class effect? *Pharmacotherapy*. 2007;27(4):526-534.
16. Jonsson A, Edner M, Alehagen U, Dahlström U. Heart failure registry: a valuable tool for improving the management of patients with heart failure. *Eur J Heart Fail*. 2010;12(1):25-31.
17. D'Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. *Stat Med*. 1998;17(19):2265-2281.
18. Pfeffer MA, Swedberg K, Granger CB, et al; CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. *Lancet*. 2003;362(9386):759-766.
19. Swedberg K, Cleland J, Dargie H, et al; Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): the Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. *Eur Heart J*. 2005;26(11):1115-1140.
20. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). *Circulation*. 2005;112(12):e154-e235.
21. Lin DY, Psaty BM, Kronmal RA. Assessing the sensitivity of regression results to unmeasured confounders in observational studies. *Biometrics*. 1998;54(3):948-963.
22. Bhuiyan MA, Ishiguro M, Hossain M, et al. Binding sites of valsartan, candesartan and losartan with angiotensin II receptor 1 subtype by molecular modeling. *Life Sci*. 2009;85(3-4):136-140.
23. Van Liefde I, Vauquelin G. Sartan-AT1 receptor interactions: in vitro evidence for insurmountable antagonism and inverse agonism. *Mol Cell Endocrinol*. 2009;302(2):237-243.
24. Vauquelin G, Fierens F, Van Liefde I. Long-lasting angiotensin type 1 receptor binding and protection by candesartan: comparison with other biphenyl-tetrazole sartans. *J Hypertens Suppl*. 2006;24(1):S23-S30.
25. Fierens F, Vanderheyden PM, De Backer JP, Vauquelin G. Binding of the antagonist [3H]candesartan to angiotensin II AT1 receptor-transfected [correction of tranfected] Chinese hamster ovary cells. *Eur J Pharmacol*. 1999;367(2-3):413-422.
26. Fierens FL, Vanderheyden PM, Gáborik Z, et al. Lys(199) mutation of the human angiotensin type 1 receptor differentially affects the binding of surmountable and insurmountable non-peptide antagonists. *J Renin Angiotensin Aldosterone Syst*. 2000;1(3):283-288.
27. Koh KK, Han SH, Chung WJ, et al. Comparison of effects of losartan, irbesartan, and candesartan on flow-mediated brachial artery dilation and on inflammatory and thrombolytic markers in patients with systemic hypertension. *Am J Cardiol*. 2004;93(11):1432-1435, A10.
28. Fridman KU, Elmfeldt D, Wysocki M, Friberg PR, Andersson OK. Influence of AT1 receptor blockade on blood pressure, renal haemodynamics and hormonal responses to intravenous angiotensin II infusion in hypertensive patients. *Blood Press*. 2002;11(4):244-252.
29. Lacourcière Y, Asmar R. A comparison of the efficacy and duration of action of candesartan cilexetil and losartan as assessed by clinic and ambulatory blood pressure after a missed dose, in truly hypertensive patients: a placebo-controlled, forced titration study. *Am J Hypertens*. 1999;12(12 pt 1-2):1181-1187.
30. McMurray JJ, Swedberg K. HEAAL: the final chapter in the story of angiotensin receptor blockers in heart failure—lessons learnt from a decade of trials. *Eur J Heart Fail*. 2010;12(2):99-103.